ATE254907T1 - Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe - Google Patents

Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe

Info

Publication number
ATE254907T1
ATE254907T1 AT99968104T AT99968104T ATE254907T1 AT E254907 T1 ATE254907 T1 AT E254907T1 AT 99968104 T AT99968104 T AT 99968104T AT 99968104 T AT99968104 T AT 99968104T AT E254907 T1 ATE254907 T1 AT E254907T1
Authority
AT
Austria
Prior art keywords
hydrogendivalproate
sodium
controlled release
release formulations
formulations
Prior art date
Application number
AT99968104T
Other languages
English (en)
Inventor
Yihong Qui
Richard P Poska
Howard S Cheskin
J Daniel Bollinger
Kevin R Engh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/216,650 external-priority patent/US6419953B1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE254907T1 publication Critical patent/ATE254907T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99968104T 1998-12-18 1999-12-09 Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe ATE254907T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/216,650 US6419953B1 (en) 1998-12-18 1998-12-18 Controlled release formulation of divalproex sodium
US12155799P 1999-02-25 1999-02-25
PCT/US1999/029204 WO2000037055A1 (en) 1998-12-18 1999-12-09 Controlled release formulation of divalproex sodium

Publications (1)

Publication Number Publication Date
ATE254907T1 true ATE254907T1 (de) 2003-12-15

Family

ID=26819594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968104T ATE254907T1 (de) 1998-12-18 1999-12-09 Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe

Country Status (25)

Country Link
EP (1) EP1140034B1 (de)
JP (1) JP2003513882A (de)
KR (1) KR20010101295A (de)
CN (1) CN1335769A (de)
AR (1) AR021443A1 (de)
AT (1) ATE254907T1 (de)
AU (1) AU2478900A (de)
BG (1) BG105665A (de)
BR (1) BR9916361A (de)
CA (1) CA2330480C (de)
CO (1) CO5160287A1 (de)
CZ (1) CZ20012201A3 (de)
DE (1) DE69913197T2 (de)
DK (1) DK1140034T3 (de)
ES (1) ES2212667T3 (de)
HK (1) HK1043043B (de)
HU (1) HUP0105463A3 (de)
IL (1) IL143407A0 (de)
NO (1) NO20012986L (de)
PL (1) PL356899A1 (de)
PT (1) PT1140034E (de)
SI (1) SI20624A (de)
SK (1) SK8252001A3 (de)
TW (1) TW585788B (de)
WO (1) WO2000037055A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
DE60219005T2 (de) * 2001-05-25 2007-12-13 Cephalon, Inc. Modafinil umfassende feste pharmazeutische Formulierungen
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040005357A1 (en) * 2002-07-03 2004-01-08 Sherman Bernard Charles Extended-release tablets comprising divalproex sodium
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
NZ542303A (en) * 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
HUP0301537A3 (en) * 2003-06-03 2005-07-28 Egis Gyogyszergyar Nyilvanosan Deramcyclane fumarate tablets and process for producing them
US7713550B2 (en) 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006025029A2 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Extended release composition of divalproex
JP2008528607A (ja) * 2005-01-26 2008-07-31 エラン・ファルマ・インターナショナル・リミテッド 抗精神薬を含む制御調節組成物
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
US8952060B2 (en) * 2009-05-12 2015-02-10 Amorepacific Corporation Composition for preventing hair loss or for stimulating hair growth
WO2012121862A2 (en) * 2011-02-17 2012-09-13 University Of Florida Research Foundation Valproic acid derivative compounds
CN102138911B (zh) * 2011-03-28 2012-12-12 孙卫东 一种双丙戊酸钠缓释片及其制备方法
CN102895201B (zh) * 2011-07-26 2014-09-10 北大方正集团有限公司 丙戊酸半钠片剂及其制备方法
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
CN105012264B (zh) * 2014-04-16 2019-11-29 四川科瑞德制药股份有限公司 丙戊酸钠缓释片及其制备工艺和用途
CN106389368B (zh) * 2015-07-29 2021-11-12 四川科瑞德制药股份有限公司 一种丙戊酸钠缓释制剂及其制备工艺和用途
CN105456218A (zh) * 2015-12-07 2016-04-06 黑龙江省智诚医药科技有限公司 一种丙戊酸镁缓释片及其制备方法
CN107028907B (zh) * 2016-02-04 2021-05-14 成都康弘药业集团股份有限公司 一种双丙戊酸钠缓释片
CN114681419A (zh) * 2020-12-28 2022-07-01 湖南省湘中制药有限公司 一种丙戊酰胺缓释片的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
TW224049B (de) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW222585B (de) * 1992-09-11 1994-04-21 Hoechst Ag
JP3552285B2 (ja) * 1993-08-03 2004-08-11 三菱化学株式会社 経口コレステロール低下剤
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity

Also Published As

Publication number Publication date
DK1140034T3 (da) 2004-03-08
EP1140034A1 (de) 2001-10-10
BR9916361A (pt) 2002-11-05
HUP0105463A3 (en) 2003-03-28
SI20624A (sl) 2002-02-28
CN1335769A (zh) 2002-02-13
NO20012986D0 (no) 2001-06-15
HUP0105463A2 (hu) 2002-05-29
DE69913197T2 (de) 2004-09-02
AU2478900A (en) 2000-07-12
EP1140034B1 (de) 2003-11-26
WO2000037055A1 (en) 2000-06-29
PT1140034E (pt) 2004-03-31
ES2212667T3 (es) 2004-07-16
BG105665A (bg) 2002-03-29
CA2330480C (en) 2002-05-21
PL356899A1 (en) 2004-07-12
AR021443A1 (es) 2002-07-17
IL143407A0 (en) 2002-04-21
KR20010101295A (ko) 2001-11-14
SK8252001A3 (en) 2001-12-03
CZ20012201A3 (cs) 2001-09-12
HK1043043B (zh) 2004-09-10
HK1043043A1 (en) 2002-09-06
TW585788B (en) 2004-05-01
CO5160287A1 (es) 2002-05-30
DE69913197D1 (de) 2004-01-08
NO20012986L (no) 2001-08-15
JP2003513882A (ja) 2003-04-15
CA2330480A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
NO20012636L (no) Kontrollert frigivelsesformulering som omfatter GNRH-II
DK1096937T3 (da) Ranolazinformuleringer med langvarig frigivelse
ATE269075T1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
PT1130966E (pt) Formulacoes antiparasitarias
DE69805443D1 (de) Sachet-formulierungen
ATE227074T1 (de) Mikrokapsel-formulierungen
MA24473A1 (fr) Formulations
DK0880892T3 (da) Midler med reguleret frigivelse
NO20002126D0 (no) Formulering med forlenget frigjøring
IS6398A (is) Lyfjablöndur
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
ATE232683T1 (de) Mikrokapsel-formulierungen
DE19983627T1 (de) Knoblauch-Formulierungen mit kontrollierter Freisetzung
NO20021452L (no) Orale kontrollerte frigivelsesformuleringer
NO20005722D0 (no) Brusetilberedninger
DE69814051D1 (de) Trennmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140034

Country of ref document: EP